NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 327 filers reported holding NOVOCURE LTD in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $565,250 | -75.8% | 35,000 | -37.7% | 0.01% | -78.6% |
Q2 2023 | $2,332,342 | -88.3% | 56,201 | -83.0% | 0.04% | -89.1% |
Q1 2023 | $19,932,381 | +19.3% | 331,433 | +45.5% | 0.39% | +47.9% |
Q4 2022 | $16,709,130 | +62.5% | 227,800 | +68.4% | 0.26% | +83.8% |
Q3 2022 | $10,280,000 | +66.6% | 135,300 | +52.4% | 0.14% | +67.1% |
Q2 2022 | $6,172,000 | +49.0% | 88,800 | +77.6% | 0.08% | +70.0% |
Q1 2022 | $4,142,000 | -77.5% | 50,000 | -79.6% | 0.05% | -75.8% |
Q4 2021 | $18,435,000 | -36.1% | 245,494 | -1.2% | 0.21% | -37.3% |
Q3 2021 | $28,868,000 | -19.4% | 248,500 | +54.0% | 0.33% | -29.5% |
Q2 2021 | $35,802,000 | +160.5% | 161,400 | +55.2% | 0.47% | +58.1% |
Q1 2021 | $13,746,000 | -72.3% | 104,000 | -63.7% | 0.30% | -73.8% |
Q4 2020 | $49,576,000 | +2021.4% | 286,500 | +1264.3% | 1.13% | +1956.4% |
Q3 2020 | $2,337,000 | -32.8% | 21,000 | -61.8% | 0.06% | -68.6% |
Q2 2019 | $3,477,000 | – | 55,000 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |